Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: A case-control study

British Journal of Cancer

Volumn 96, Issue 5, 2007, Pages 850-855

  Swerdlow, A J ^a   Jones, M E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Ovarian cancer; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CLIMACTERIUM; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERIMENOPAUSE; PREMENOPAUSE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33847732667     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603605     Document Type: Article

References (21)

1. Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. Volume 1-The Analysis of Case- Control Studies IARC Scientific Publications No. 32 Lyon: International Agency for Research on Cancer
2. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL (2004) Ovarian cancer risk after the use of ovulationstimulating drugs. Obstet Gynecol 103: 1194-1203
3. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87: 1359-1364
4. Curtis RE, Boice Jr JD, Shriner DA, Hankey BF, Fraumeni Jr JF (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88: 832-834
5. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
6. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, other National Surgical Adjuvant Breast and Bowel Project Investigators (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388
7. Ford D (2000) Genetic epidemiology of breast ovarian cancer. Doctor of Philosophy Thesis. London: The Institute of Cancer Research, University of London
8. Gerhard I, Runnebaum B (1979) Comparison between tamoxifen and clomiphene therapy in women with anovulation. Arch Gynecol 227: 279-288
9. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488-1491
10. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon Y-J, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF, and the Breast Cancer Linkage Consortium (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11: 5175-5180
11. Messinis IE, Nillius SJ (1982) Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet Gynecol Scand 61: 377-379
12. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155: 217-224
13. Neven P, Goldstein SR, Ciaccia AV, Zhou L, Silfen SL, Muram D (2002) The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol 85: 388-390
14. Newcomb PA, Solomon C, White E (1999) Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 53: 271-277
15. Powles TJ, Jones AL, Ashley SE, O'Brien MER, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA, Davey JB (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73-82
16. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331: 771-776
17. Rubagotti A, Perrotta A, Casella C, Boccardo F (1996) Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer. Ann Oncol 7: 239-244
18. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N, for the Stockholm Breast Cancer Study Group (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645-651
19. Spicer DV, Pike MC, Henderson BE (1991) Ovarian cancer and long-term tamoxifen in premenopausal women. Lancet 337: 1414
20. Swerdlow AJ, Jones ME, for the British tamoxifen Second Cancer Study Group. (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97: 375-384
21. Tomatis L, Aitio A, Day NE, Heseltine E, Kaldor J, Miller AB, Parkin DM, Riboli E (eds) (1990) Cancer: Causes, occurrence and control. IARC Scientific Publications, No. 100 Lyon: International Agency for Research on Cancer